Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alsoKnownAs |
gptkb:Apalutamide
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L02BB05
|
| gptkbp:CASNumber |
956104-40-8
|
| gptkbp:chemicalFormula |
C21H15F4N5O2
|
| gptkbp:developedBy |
gptkb:Janssen_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
AFP-675
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Erleada
|
| gptkbp:mechanismOfAction |
androgen receptor inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
falls
fatigue hypertension fractures rash |
| gptkbp:usedFor |
treatment of prostate cancer
|
| gptkbp:bfsParent |
gptkb:STS-39
|
| gptkbp:bfsLayer |
6
|